BAILII is celebrating 24 years of free online access to the law! Would you consider making a contribution?
No donation is too small. If every visitor before 31 December gives just £1, it will have a significant impact on BAILII's ability to continue providing free access to the law.
Thank you very much for your support!
[Home] [Databases] [World Law] [Multidatabase Search] [Help] [Feedback] | ||
Irish Statutory Instruments |
||
You are here: BAILII >> Databases >> Irish Statutory Instruments >> Irish Medicines Board (Fees) Regulations 2012.S.I. No. 572/2012 URL: http://www.bailii.org/ie/legis/num_reg/2012/0572.html |
[New search] [Help]
Notice of the making of this Statutory Instrument was published in |
||||||||||||||||||||||||||||||||||
-�Iris Oifigiúil-� of 1st January, 2013. |
||||||||||||||||||||||||||||||||||
I, James Reilly, Minister for Health, in exercise of the powers conferred on me by sections 13 and 32 (as amended by sections 15 and 16 of the Irish Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make the following Regulations: |
||||||||||||||||||||||||||||||||||
1. These Regulations may be cited as the Irish Medicines Board (Fees) Regulations 2012. |
||||||||||||||||||||||||||||||||||
2. (1) In these Regulations-� |
||||||||||||||||||||||||||||||||||
-�Act-� means the Irish Medicines Board Act 1995 (No. 29 of 1995), as amended by s. 197 of the Finance Act 1999 (No. 2 of 1999), Regulation 3 of the European Communities (In Vitro Diagnostic Medical Devices) Regulations 2001 ( S.I. No. 304 of 2001 ), Regulation 2 of the European Communities (Medical Devices) (Amendment) Regulations 2001 ( S.I. No. 444 of 2001 ), Regulation 3 of the European Communities (Medical Devices) (Amendment) Regulations 2002 ( S.I. No. 576 of 2002 ), the Irish Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006) and by the European Communities (Amendment of the Medicines Board Act 1995) Regulations 2007 ( S.I. No. 542 of 2007 ); |
||||||||||||||||||||||||||||||||||
-�Board-� means the Irish Medicines Board established by section 3 of the Act; |
||||||||||||||||||||||||||||||||||
-�certificate of free sale-� means a certificate of free sale issued under section 4(1)(k)(ii) of the Act; |
||||||||||||||||||||||||||||||||||
-�certificate of registration-� means a certificate of registration granted pursuant to the Medicinal Products (Control of Placing on the Market) Regulations 2007 ( S.I. No. 540 of 2007 ); |
||||||||||||||||||||||||||||||||||
-�certificate of traditional-use registration-� means a certificate of traditional-use registration granted pursuant to the Medicinal Products (Control of Placing on the Market) Regulations 2007 in respect of a traditional herbal medicinal product; |
||||||||||||||||||||||||||||||||||
-�certification of documents-� means the certification, under section 4(1)(k)(ii) of the Act, of documents not being certificates of free sale or export certificates; |
||||||||||||||||||||||||||||||||||
-�complex dossier-� refers to an application accompanied by a full dossier in accordance with Directive 2001/83/EC; |
||||||||||||||||||||||||||||||||||
-�decentralised procedure-� means the decentralised procedure for human medicinal products provided for in Directive 2001/83/EC; |
||||||||||||||||||||||||||||||||||
-�Directive 2001/83/EC-� means Directive 2001/83/EC of the European Parliament and of the Council of 6 November 20011 on the Community code relating to medicinal products for human use, as amended by Directive 2002/98/EC of the European Parliament and of the Council of 27 January 20032 , Commission Directive 2003/63/EC of 25 June 20033 , Directive 2004/24/EC of the European Parliament and of the Council of 31 March 20044 , Directive 2004/27/EC of the European Parliament and of the Council of 31 March 20045 , Regulation (EC) No. 1901/2006 of the European Parliament and of the Council of 12 December 20066 , Regulation (EC) No. 1394/2007 of the European Parliament and of the Council of 13 November 20077 , Directive 2008/29/EC of the European Parliament and of the Council of 11 March 20088 , Directive 2009/53/EC of the European Parliament and of the Council of 18 June 20099 , Commission Directive 2009/120/EC of 14 September 200910 , Directive 2010/84/EU of the European Parliament and of the Council of 15 December 201011 , Directive 2011/62/EU of the European Parliament and of the Council of 8 June 201112 and Directive 2012/26/EU of the European Parliament and of the Council of 25 October 201213 . |
||||||||||||||||||||||||||||||||||
-�export certificate-� means a certificate issued under section 4(1)(k)(ii) of the Act; |
||||||||||||||||||||||||||||||||||
-�homeopathic medicinal product-� has the meaning assigned to it by the Medicinal Products (Control of Placing on the Market) Regulations 2007; |
||||||||||||||||||||||||||||||||||
-�manufacturer-�s authorisation-� means an authorisation granted pursuant to the Medicinal Products (Control of Manufacture) Regulations 2007 ( S.I. No. 539 of 2007 ); |
||||||||||||||||||||||||||||||||||
-�marketing authorisation-� means an authorisation granted pursuant to the Medicinal Products (Control of Placing on the Market) Regulations 2007; |
||||||||||||||||||||||||||||||||||
-�mutual recognition procedure-� means the mutual recognition procedure for human medicinal products provided for in Directive 2001/83/EC; |
||||||||||||||||||||||||||||||||||
-�national rules scheme-� means the national rules governing the granting of marketing authorisation in respect of homeopathic medicinal products, as provided in Regulation 11 of the Medicinal Products (Control of Placing on the Market) Regulations 2007; |
||||||||||||||||||||||||||||||||||
-�parallel import licence-� has the meaning assigned to it by the Medicinal Products (Control of Placing on the Market) Regulations 2007; |
||||||||||||||||||||||||||||||||||
-�reduced dossier -� complex-� refers to an application for a generic medicinal product accompanied by a reduced dossier but containing additional data in circumstances required by Directive 2001/83/EC; |
||||||||||||||||||||||||||||||||||
-�reduced dossier -� standard-� refers to an application for a generic medicinal product accompanied by a reduced dossier in accordance with Directive 2001/83/EC; |
||||||||||||||||||||||||||||||||||
-�service item-� means an application for a medicinal product designated by the Board as qualifying for a reduced application fee on the basis that the product has limited but important uses for which no alternative authorised product exists; |
||||||||||||||||||||||||||||||||||
-�subsequent extension applications-� means applications in relation to additional pharmaceutical forms and strengths of a medicinal product, made subsequent to the first application in relation to that product; |
||||||||||||||||||||||||||||||||||
-�switching applications-� means applications for a change in the classification of medicinal products under Title VI of Directive 2001/83/EC; |
||||||||||||||||||||||||||||||||||
-�traditional herbal medicinal product-� has the meaning assigned to it by the Medicinal Products (Control of Placing on the Market) Regulations 2007; |
||||||||||||||||||||||||||||||||||
-�type IB variation-� and -�type II standard variation-� shall be classified by the Board in accordance with Commission Regulation (EC) No. 1234/2008 of 24 November 200814 , as amended by Commission Regulation (EU) No 712/2012 of 3 August 201215 ; |
||||||||||||||||||||||||||||||||||
-�wholesaler-�s authorisation-� means an authorisation granted pursuant to the Medicinal Products (Control of Wholesale Distribution) Regulations 2007; |
||||||||||||||||||||||||||||||||||
(2) In these Regulations, unless otherwise indicated-� |
||||||||||||||||||||||||||||||||||
(a) any reference to a Regulation is a reference to a Regulation of these Regulations, and |
||||||||||||||||||||||||||||||||||
(b) any reference to the Schedule is a reference to the Schedule to these Regulations. |
||||||||||||||||||||||||||||||||||
3. Subject to Regulation 4, there shall be paid to the Board in respect of each and every matter set out in column 1 of the Schedule the fee as set out in column 2 of the Schedule. |
||||||||||||||||||||||||||||||||||
4. The Board may, in circumstances where it considers it appropriate to do so, waive, remit or refund, either in whole or in part, any fee that would otherwise be payable to it under Regulation 3. |
||||||||||||||||||||||||||||||||||
5. The Irish Medicines Board (Fees) Regulations 2011 ( S.I. No. 684 of 2011 ) are hereby revoked. |
||||||||||||||||||||||||||||||||||
SCHEDULE |
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
(Note: Companies classed as both manufacturer and wholesaler are charged the higher of the two applicable charges. Marketing authorisation holders pay the marketing authorisation holder fee in addition to any manufacturer / wholesaler fee.) |
||||||||||||||||||||||||||||||||||
GIVEN under my Official Seal, |
||||||||||||||||||||||||||||||||||
21 December 2012. |
||||||||||||||||||||||||||||||||||
JAMES REILLY, |
||||||||||||||||||||||||||||||||||
Minister for Health. |
||||||||||||||||||||||||||||||||||
EXPLANATORY NOTE |
||||||||||||||||||||||||||||||||||
(This note is not part of the Instrument and does not purport to be a legal instrument.) |
||||||||||||||||||||||||||||||||||
The purpose of these Regulations is to provide for the revision of fees payable to the Irish Medicines Board pursuant to Section 13 of the Irish Medicines Board Act 1995 . |
||||||||||||||||||||||||||||||||||
These Regulations revoke the Irish Medicines Board (Fees) Regulations 2011 ( S.I. No. 684 of 2011 ). |
||||||||||||||||||||||||||||||||||
1 OJ No. L 311, 28.11.2001, p. 67. 2 OJ No. L 33, 8.2.2003, p. 30. 3 OJ No. L 159, 27.6.2003, p. 46. 4 OJ No. L 136, 30.4.2004, p. 85. 5 OJ No. L 136, 30.4.2004, p. 34. 6 OJ No. L 378, 27.12.2006, p. 1. 7 OJ No. L 324, 10.12.2007, p. 121. 8 OJ No. L 81, 20.3.2008, p. 51. 9 OJ No. L 168, 30.6.2009, p. 33. 10 OJ No. L 242, 15.9.2009, p. 3. 11 OJ No. L 348, 31.12.2010, p. 74. 12 OJ No. L 174, 1.7.2011, p. 74. 13 OJ No. L 299, 27.10.2012, p. 1. |